<i>Leishmania donovani</i> Dipeptidylcarboxypeptidase Inhibitor as a Potential Oral Treatment for Visceral Leishmaniasis-Reference-Cited by-同舟云学术

Leishmania donovani Dipeptidylcarboxypeptidase Inhibitor as a Potential Oral Treatment for Visceral Leishmaniasis

Published:2022-08-16 Issue:8 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Ramalingam Karthik¹,Gangwar Sonali¹²,Balodi Deep Chandra¹²,Anand Apeksha¹²,Yadav Shailendra¹²,Biswas Subhasish³,Karunakaran Sasikala Anil Kumar³,Gupta Kailash Chand⁴,Batra Sanjay³²,Goyal Neena¹²^ORCID

Affiliation:

1. Division of Biochemistry and Structural Biology, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India

2. Academy of Scientific and Innovative Research, CSIR-Human Resource Development Centre, Ghaziabad, Uttar Pradesh, India

3. Division of Medicinal and Process Chemistry, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, India

4. Department of Chemistry, University of Delhi, Delhi, India

Abstract

Chemotherapy is the key intervention to control visceral leishmaniasis (VL), a neglected tropical disease. Current regimens include not only a few drugs but also present several drawbacks, including moderate to severe toxicity, cost, long-term administration, patient compliance, and growing drug resistance.

Funder

Council of Scientific and Industrial Research, India

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.02361-21

Reference24 articles.

1. Leishmaniasis Worldwide and Global Estimates of Its Incidence

2. World Health Organization. 2010. Control of the leishmaniases. WHO Technical Report Series no. 949. World Health Organization Geneva Switzerland. http://whqlibdoc.who.int/trs/WHO_TRS_949_eng.pdf.

3. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?

4. Current diagnosis and treatment of visceral leishmaniasis

5. Drug Resistance in Visceral Leishmaniasis

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigational new drugs for the treatment of leishmaniasis;Expert Opinion on Investigational Drugs;2024-09-10

2. Novel chemical scaffold as potential drug against Leishmania donovani: Integrated computational and experimental approaches;Journal of Cellular Biochemistry;2023-08-11